According to the Zhitong Finance App, Yao Ming Junuo-B (02126) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 174 million yuan (RMB, same below) during the period, an increase of 19.32%; gross profit of 882.19 million yuan, an increase of 50.14% over the previous year; and R&D expenditure of 414 million yuan, an increase of 1.42% over the previous year.

According to the announcement, the increase in revenue was due to the Group's CD19 autochimeric antigen receptor T cell (CAR-T) immunotherapy product Benoda(rekiolense injection (relma-cel), R&D code: JWCAR029) continues to be commercialized. BenodaApproved to treat recurrent or refractory (r/r) large B-cell lymphoma (LBCL) and r/r follicular lymphoma (FL) in adult patients. As the market continues to develop, the Group expects BenodatSales revenue will continue to increase, excellent product characteristics can bring breakthrough value to patients, and more indications are expected to be approved.

For the year ended December 31, 2023, as an independent innovative biotechnology company focusing on the development, production and commercialization of cellular immunotherapy products, the Group made further significant progress in its business and achieved important milestones. Operational efficiency was improved across the board, such as further increase in gross margin, good control of sales expenses, organizational streamlining, and reduction in net cash outflow. Benoda, the Group's leading productSignificant progress continues to be made in commercialization. Furthermore, with excellent clinical development and operation capabilities, China's National Drug Administration (China Drug Administration) has approved the relevant BenodarNew clinical research drug (IND) application for second-line treatment of r/rLBCL patients who are not eligible for transplantation, and patients who have already carried out relevant clinical trials have been enrolled in the group. The State Drug Administration has further approved BenodatNew complementary drug applications for the treatment of patients with r/r mantle cell lymphoma (MCL); and related BenodatIND application for the treatment of systemic lupus erythematosus (SLE). The Group is currently expecting BenodatIt is expected to be the first cell therapy product approved for the treatment of r/RMCL patients in China. The Group also initiated the Investigator-Initiated Trial (IIT) of JWATM214 to treat advanced hepatocellular carcinoma (HCC). Furthermore, the Group has made significant progress in developing innovative products with global commercialization potential.